Apyx Medical Corporation (NASDAQ:APYX) is a leading advanced energy medical technology company that specializes in developing, manufacturing, and marketing innovative helium plasma and radiofrequency (RF) products for the surgical and aesthetic markets. Headquartered in Clearwater, Florida, the company is best known for its proprietary Renuvion® and AYON® Body Contouring System™ platforms—cutting-edge technologies designed to provide precise, controlled energy delivery for tissue contraction and skin tightening with minimal thermal damage. With a foundation rooted in scientific innovation and decades of engineering excellence, Apyx Medical has positioned itself as a transformative force in the rapidly expanding field of surgical aesthetics and minimally invasive medical procedures.
Originally operating under the name Bovie Medical, the company underwent a strategic transformation to focus entirely on advanced energy-based technologies and rebranded as Apyx Medical Corporation. This shift marked a pivotal moment in its evolution, allowing it to direct resources toward research, regulatory development, and commercialization of next-generation plasma and RF-based systems. Today, Apyx Medical’s technology is used by surgeons and aesthetic practitioners worldwide to deliver superior clinical outcomes, reduce patient downtime, and redefine standards in both aesthetic body contouring and general surgery.
The company’s flagship Renuvion® technology has earned global recognition for its groundbreaking use of helium plasma and RF energy to achieve controlled heating and cooling of tissue in real time. This unique combination enables exceptional precision and safety during procedures, making it a preferred choice among plastic surgeons, dermatologists, and cosmetic physicians. Renuvion’s versatility allows it to be used in both open and minimally invasive applications, offering benefits across a wide range of procedures including skin tightening, facial rejuvenation, and body contouring. The technology’s expanding list of indications has solidified Apyx’s reputation as a leader in the field of advanced energy surgery.
Building on the success of Renuvion®, Apyx introduced its AYON® Body Contouring System™, a next-generation energy-based platform designed to deliver even more versatility and performance in body contouring and soft tissue coagulation. AYON represents the company’s commitment to continuous innovation and its ability to anticipate market trends in aesthetic medicine. Engineered with enhanced user ergonomics, advanced safety features, and real-time feedback mechanisms, the AYON system has received overwhelmingly positive reviews from leading plastic and cosmetic surgeons since its U.S. commercial launch in 2025. The device’s precision, ease of use, and consistent clinical results have positioned it as a new benchmark in aesthetic energy devices.
Beyond aesthetics, Apyx Medical continues to expand its footprint in the broader surgical market through its OEM (Original Equipment Manufacturer) business segment. This division supplies advanced energy components and systems to other medical device manufacturers, contributing to both revenue diversification and technological integration across multiple healthcare applications. The company’s dual-segment business model—spanning Surgical Aesthetics and OEM—enables it to maintain steady growth while investing heavily in research and development aimed at advancing plasma-based technologies for future surgical innovations.
Apyx Medical’s long-term growth strategy revolves around expanding its global presence, strengthening its intellectual property portfolio, and broadening clinical indications for its core technologies. The company has made significant strides in regulatory affairs, achieving multiple FDA clearances and pursuing additional approvals for expanded use cases such as power-assisted liposuction. With the growing global demand for minimally invasive aesthetic procedures, Apyx is strategically positioned to capture a larger share of the $15 billion aesthetic energy device market.
Under the leadership of President and CEO Charlie Goodwin, Apyx Medical has adopted a results-driven approach that emphasizes innovation, surgeon education, and operational excellence. Goodwin’s vision centers on making Apyx synonymous with innovation in advanced energy-based medical technology. Through strategic investments in commercialization, clinical research, and international expansion, the company is unlocking new growth opportunities across North America, Europe, and emerging markets.
Financially, Apyx Medical has shown resilience and growth, consistently improving gross margins and narrowing losses while expanding its revenue base. Its upwardly revised 2025 guidance, fueled by strong demand for the AYON® Body Contouring System™, reflects the company’s success in scaling commercialization efforts and managing operational costs effectively. With a product pipeline designed to meet evolving patient and surgeon needs, Apyx Medical is well-positioned for sustained growth in the years ahead.
At its core, Apyx Medical Corporation represents the convergence of science, precision, and innovation in modern medicine. By leveraging its proprietary helium plasma and RF technologies, the company continues to push the boundaries of what is possible in surgical and aesthetic procedures. As it advances its mission to deliver safer, smarter, and more effective energy-based solutions, Apyx Medical stands at the forefront of a rapidly changing healthcare landscape—one where technology, artistry, and patient outcomes intersect to define the future of medical aesthetics and surgery.
Record Growth and Strategic Expansion Set the Stage for a Transformative 2026
Apyx Medical Corporation (NASDAQ:APYX), a pioneering leader in advanced energy solutions for surgical and aesthetic applications, continues to build impressive momentum as it delivers another quarter of strong performance and strategic progress. Known globally for its innovative Renuvion® technology and the newly launched AYON® Body Contouring System™, the company’s third-quarter 2025 results highlight accelerating adoption of its proprietary helium plasma and radiofrequency energy platforms across the expanding aesthetic and surgical markets. As the demand for minimally invasive and precision-based procedures continues to rise, Apyx Medical’s consistent growth, margin expansion, and product innovation underline a compelling bullish outlook for long-term investors.
For the quarter ending September 30, 2025, Apyx Medical reported total revenue of $12.9 million, representing a 12.1% year-over-year increase from $11.5 million in the same period of 2024. This growth was primarily driven by a 19% surge in Surgical Aesthetics revenue, which reached $11.1 million due to the strong commercial performance of the AYON Body Contouring System™. While OEM revenue declined by 18% to $1.8 million amid lower sales volumes to existing customers, this temporary dip was overshadowed by the growing strength of the company’s aesthetic segment, which now serves as its primary growth engine.
CHECK THIS OUT: Corcept (CORT) Skyrockets 1,534% in 10 Years and Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer.
Financial Results Demonstrate Strengthening Fundamentals and Margin Expansion
Apyx Medical’s third-quarter 2025 results mark a turning point toward improved profitability and operational efficiency. The company reported a net loss of $2.0 million, significantly reduced from the $4.7 million net loss recorded in Q3 2024. Furthermore, adjusted EBITDA loss shrank dramatically to just $0.1 million, down from $2.4 million in the prior year period — underscoring effective cost management and higher gross margin performance. Gross profit increased to $8.3 million, compared with $7.0 million in the same quarter last year, while gross margin expanded to 64.4%, up from 60.5% year-over-year.
This sharp improvement in gross margin reflects not only the success of AYON’s commercial rollout but also the optimization of manufacturing processes and better product mix. The company’s ability to simultaneously drive revenue growth and improve margin efficiency positions it well for sustainable profitability. With operating expenses remaining under control, the path toward positive adjusted EBITDA on a full-year basis appears increasingly attainable.
AYON Body Contouring System™: Redefining the Future of Surgical Aesthetics
The primary catalyst behind Apyx Medical’s current and future growth lies in the AYON Body Contouring System™, an advanced energy device that utilizes helium plasma and radiofrequency energy to deliver precise tissue contraction with minimal thermal damage. Following a successful soft launch earlier in the year, the company announced in September 2025 that AYON had transitioned to a full-scale U.S. commercial launch, marking a major inflection point in its market penetration strategy.
The AYON system has garnered exceptional feedback from top plastic and cosmetic surgeons across the United States, who praise its superior precision, shorter recovery times, and enhanced procedural versatility. To further expand its clinical utility, Apyx submitted a new 510(k) premarket notification to the FDA seeking label expansion for AYON to include power-assisted liposuction (PAL) — a move expected to significantly broaden its addressable market. Once approved, this expansion could establish AYON as the gold standard in energy-assisted body contouring, positioning the company to capture market share from both traditional liposuction and competing RF-based systems.
The AYON platform also complements Apyx’s flagship Renuvion® technology, which is already recognized for its groundbreaking helium plasma innovation. Together, these systems offer a complete suite of minimally invasive solutions that address the growing global demand for body contouring, skin tightening, and aesthetic enhancement procedures. With increasing consumer preference for non-surgical alternatives and physicians seeking versatile, clinically proven technologies, Apyx Medical is positioned at the forefront of one of the most lucrative trends in the medtech industry.
Strategic Expansion and Global Market Penetration
Under the leadership of President and CEO Charlie Goodwin, Apyx Medical is aggressively scaling its operations to meet surging demand. The company’s transition from a soft launch to a full U.S. commercialization of AYON reflects management’s confidence in the device’s market potential and growing surgeon adoption. Goodwin emphasized that the company is now focused on accelerating the adoption curve by broadening its surgeon base and increasing case utilization across key practices nationwide.
Internationally, Apyx is laying the groundwork for broader expansion through regulatory clearances and distribution partnerships. As the global surgical aesthetics market experiences double-digit growth — fueled by rising disposable incomes, shifting beauty standards, and advancements in energy-based technologies — Apyx Medical’s entry into new regions could unlock significant revenue streams over the next few years.
The company’s Renuvion® system continues to serve as an international growth driver, supported by its proven safety profile and expanding clinical indications. As new markets adopt minimally invasive energy-assisted procedures, the combination of Renuvion and AYON creates a robust product ecosystem that addresses a wide spectrum of patient needs, from subtle skin tightening to large-area body contouring.
Revised Full-Year Guidance and Financial Outlook
Reflecting the strong momentum achieved in the third quarter, Apyx Medical raised its full-year 2025 revenue guidance to a range of $50.5 million to $52.5 million, up from prior estimates. Within this, Surgical Aesthetics revenue is projected between $43 million and $45 million, while OEM revenue is expected to reach approximately $7.5 million. Management also expects total operating expenses to remain below $40 million for the year, demonstrating continued financial discipline even as the company invests in commercialization and R&D initiatives.
The improved revenue guidance signals that Apyx’s business transformation is yielding tangible results. If the company continues to scale the AYON product line and achieve incremental margin expansion, its trajectory toward profitability could accelerate as early as 2026. With gross margins consistently in the mid-60% range and declining losses, Apyx Medical has created a strong financial foundation for sustained growth and shareholder value creation.
Management’s Confidence and Vision for 2026
In his statement following the Q3 earnings release, CEO Charlie Goodwin highlighted the company’s exceptional progress in commercial execution and the overwhelmingly positive feedback from surgeons using the AYON system. He reaffirmed Apyx’s commitment to expanding its user base and accelerating adoption across the surgical aesthetics market. Goodwin also pointed to the company’s proactive engagement with regulatory authorities and its ongoing investments in innovation as key components of its long-term growth plan.
Heading into 2026, Apyx Medical is expected to benefit from multiple growth drivers: the full-scale commercialization of AYON, FDA approval of its label expansion for power-assisted liposuction, and deeper penetration into international markets. As the company transitions from a phase of operational restructuring to one of sustained growth, it is emerging as a dominant force in minimally invasive energy-based technology.
Conclusion: Apyx Medical Poised for High-Growth Revaluation
Apyx Medical Corporation (NASDAQ: APYX) is entering one of the most exciting growth phases in its history. With third-quarter 2025 results showing $12.9 million in revenue, 64.4% gross margin, and a dramatically reduced net loss of $2 million, the company is proving its ability to combine top-line growth with operational discipline. The AYON Body Contouring System™, now in full commercial launch, has already established itself as a disruptive innovation in surgical aesthetics, and upcoming regulatory milestones promise to expand its addressable market even further.
Backed by a strong management team, increasing surgeon adoption, rising gross margins, and an upwardly revised full-year outlook, Apyx Medical stock (NASDAQ: APYX) represents a compelling bullish opportunity in the medtech sector. As the global aesthetic devices market continues to grow rapidly, Apyx is uniquely positioned to capture market share and deliver substantial shareholder value. For investors seeking exposure to a high-potential medical technology company with proven innovation and a clear path to profitability, Apyx Medical stands out as one of the most promising growth stories heading into 2026 and beyond.
READ ALSO: Tiziana (TLSA) Surges 143% in 2025 and Immuneering (IMRX) Reports 86% 9-Month Survival in Pancreatic Cancer.
